Hepatic Encephalopathy Clinical Trials 2023

What are the top hospitals conducting hepatic encephalopathy research?

In the realm of hepatic encephalopathy, several hospitals are making significant strides in clinical trials to enhance our understanding and treatment of this condition. The Inland Empire Liver Foundation, located in Rialto, California, has emerged as a leading institution with two active trials dedicated to hepatic encephalopathy. Although their overall count stands at just three trials since recording their first one in 2013, their commitment remains unwavering. Meanwhile, Bausch Site 501 in New Orleans and Bausch Site 525 in Chandler have also joined the quest for advancements by each conducting one active trial alongside their respective inaugural studies recorded recently in 2022.

Similarly contributing to these efforts are Bausch Site 562 in Phoenix and Bausch Site 539 in Little Rock—both actively engaged in hepatic encephalopathy research through one ongoing clinical trial while sharing the same commendable record of one previous study dating back to this year as well.

Hepatic encephalopathy poses unique challenges as it is a complex neurological disorder that arises from liver dysfunction. It occurs when toxins accumulate due to liver failure or impairment, affecting cognitive function and potentially leading to severe complications if left untreated. These selected hospitals demonstrate a dedication not only towards improving patient outcomes but also towards unraveling the mysteries surrounding this condition.

By participating actively in clinical trials on hepatic encephalopathy and pushing boundaries through innovative research protocols, these institutions offer hope for those living with this challenging condition. Each new trial brings us closer to uncovering more effective treatments and interventions that can ultimately transform lives affected by hepatic encephalopathy worldwide.

Which are the best cities for hepatic encephalopathy clinical trials?

When it comes to hepatic encephalopathy clinical trials, several cities have emerged as leading hubs for research and advancements. Houston, Texas takes the lead with 10 active trials investigating treatments like Rifaximin SSD, High-dose methylprednisolone, and Rifaximin. New york, New York and Richmond, Virginia follow closely behind with 7 ongoing studies each that explore similar interventions including Rifaximin SSD and Fecal Microbial Transplant Enema. Dallas, Texas also makes the list with 6 active trials focusing on therapies such as Rifaximin SSD and High-dose methylprednisolone. Lastly, Los Angeles, California contributes to this important field of study with 5 active trials examining treatment options like Rifaximin and High-dose methylprednisolone. These cities collectively represent centers of excellence where individuals affected by hepatic encephalopathy can access innovative clinical trials that pave the way for improved care outcomes.

Which are the top treatments for hepatic encephalopathy being explored in clinical trials?

Exciting developments are underway in clinical trials exploring treatments for hepatic encephalopathy. Currently, the top contenders include Rifaximin SSD, PPI deprescribing, and high-dose methylprednisolone. These three therapies show promise with their involvement in active trials dedicated to combating this condition. Additionally, RBX7455 and Ensure Enlive have also emerged as potential options worth investigating further. As researchers delve deeper into these treatment avenues, they hold the key to enhancing the quality of life for individuals affected by hepatic encephalopathy.

What are the most recent clinical trials for hepatic encephalopathy?

Exciting advancements in the field of hepatic encephalopathy are emerging through recent clinical trials. One such trial focuses on the efficacy of Rifaximin SSD, a promising treatment option for this condition. With Phase 3 studies demonstrating encouraging results, there is hope that Rifaximin SSD could provide much-needed relief to patients suffering from hepatic encephalopathy. Additionally, high-dose methylprednisolone has shown potential as a therapeutic intervention in Phase 2 trials, while PPI deprescribing is being explored as a strategy in both Phase 1 and Phase 2 studies. VE303, another innovative approach being investigated in a Phase 2 trial conducted last year, offers further promise for improved outcomes and enhanced quality of life for individuals with hepatic encephalopathy. These ongoing trials hold great significance for future treatments within this challenging medical domain.

What hepatic encephalopathy clinical trials were recently completed?

Recently completed clinical trials have made significant strides in the field of hepatic encephalopathy. In September 2019, Hunter Holmes Mcguire Veteran Affairs Medical Center successfully concluded a trial evaluating the effectiveness of Rifamycin SV MMX. Likewise, in June 2018, another study sponsored by the same medical center investigated the use of 25% IV albumin for this condition. These trials offer valuable insights and potential treatment options for individuals affected by hepatic encephalopathy.